Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 25Kidney Neoplasms 4Carcinoma, Renal Cell 3Skin Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Seminoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Interferon-alpha 1Imiquimod 13-ingenyl angelate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Facies × Interferon-alpha × Dermatologic × Clear all
NCT00581425 2013-01-25

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

The University of Texas Health Science Center, Houston

Phase 4 Completed
49 enrolled
Dermatologic

Carcinoma, Basal Cell, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡